This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1916)
- Annex to CHMP highlights(367)
- Annual Report(94)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1980)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2711)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(141)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Overview(1976)
- EPAR - Paediatric investigation plan compliance statement(89)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1976)
- EPAR - Public assessment report(1551)
- EPAR - Risk-management-plan summary(1144)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(72)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(24)
- Minutes(1250)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4061)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2763)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5491)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5308)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2782)
- Regulatory and procedural guideline(723)
- Report(1620)
- Scientific guideline(2465)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1675)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)Maximum Residue Limits - Report(804)
- (-)PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- Advanced therapies(0)
- Antimicrobial resistance(0)
- Biologicals(0)
- Biosimilars(0)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(0)
- Corporate(0)
- COVID-19(0)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(0)
- Governance(0)
- Innovation(0)
- Maximum residue limit(804)
- Medication error(0)
- Medicines(841)
- Medicines for use outside the EU(0)
- Medicine shortages(0)
- Mpox(0)
- Paediatrics(105)
- Parallel distribution(0)
- Pharmacovigilance(1)
- Procurement(0)
- Product information(0)
- Quality of medicines(0)
- Rare diseases(0)
- Referrals(0)
- Regulatory and procedural guidance(0)
- Research and development(2)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(0)
- Veterinary limited markets(0)
Search results (913)
Sodium salicylate (poultry other than turkey): European Public MRL Assessment Report (EPMAR) - CVMP
English (EN) (275.49 KB - PDF)
Verinurad / allopurinol : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (53.96 KB - PDF)
N-(3-cyano-4-fluorophenyl)-1-methyl-4-[[(2S)-1,1,1-trifluoro-2- propanyl]sulfamoyl]-1H-pyrrole-2.....(JNJ-56136379) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (97.42 KB - PDF)
Fusion protein composed of the first 2 immunoglobulin-like domains of the human roundabout guidance receptor 2 fused to a human IgG1....(PF-06730512) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (59.74 KB - PDF)
Atrasentan (hydrochloride) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (62.38 KB - PDF)
Ketoprofen : call for scientific data for use in CVMP assessment work of ketoprofen: review of the CVMP opinion for the establishment of maximum residue limits
English (EN) (147.59 KB - PDF)
Ibrutinib : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (73.88 KB - PDF)
Alpha1-proteinase inhibitor (human) (A1-PI) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (102.01 KB - PDF)
Alpha1-proteinase inhibitor (human) (A1-PI) : Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (101.53 KB - PDF)
Discontinuation - Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision
English (EN) (89.6 KB - PDF)